Summary
This white paper discusses the implementation of AI-driven case intake solutions in pharmacovigilance (PV) systems, addressing the challenges faced by organizations in managing adverse event reporting. It outlines the critical role of pharmacovigilance case intake in ensuring compliance with regulatory requirements and maintaining patient safety. The document details the benefits of AI-assisted case processing, including reduced case cycle times, improved consistency, and enhanced scalability. It also identifies barriers to adoption, such as high implementation costs and the need for extensive training datasets. The paper highlights two significant factors that have facilitated AI adoption: the surge in adverse event reports during the Covid-19 vaccine rollout and the availability of large language models. Additionally, it presents five key considerations for successful implementation, emphasizing the importance of balancing automation with human oversight, managing reporting format variability, and assessing technology costs against return on investment. The conclusion reflects on the evolving landscape of AI in pharmacovigilance.
